Radiation plus immunotherapy before lung surgery shows promise in early trial

NCT ID NCT05500092

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at whether adding a precise, high-dose form of radiation (SBRT) to standard chemotherapy and immunotherapy (nivolumab) before surgery can improve outcomes for people with stage IIA to IIIB non-small cell lung cancer. About 17 participants were randomly assigned to receive either the standard combination or the combination plus radiation. The main goal is to see how many patients have no cancer cells left in their removed tumor tissue after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE IIA TO IIIB NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Montefiore Medical Center-Albert Einstein College of Medicine

    The Bronx, New York, 10461, United States

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania, 17033, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63130, United States

  • White Plains Hospital (WPH)

    White Plains, New York, 10601, United States